DFN-02 Open Label Safety Study in Patients With Acute Migraine

Trial Profile

DFN-02 Open Label Safety Study in Patients With Acute Migraine

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs DFN 02 (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 07 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.
    • 18 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top